Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: IONS

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $33

By Benzinga Newsdesk
January 23, 7:38 AM
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $32 to $33.

IONS

Read More
1 minute read
  • Analyst Ratings

Analyst Expectations for Ionis Pharmaceuticals’s Future

By Benzinga Insights
January 19, 2:00 PM
Over the past 3 months, 5 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts…

IONS

Read More
1 minute read
  • Analyst Ratings

The Latest Analyst Ratings for Ionis Pharmaceuticals

By Benzinga Insights
December 21, 3:07 PM
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

IONS

Read More
14 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For December 21, 2022

By Benzinga Insights
December 21, 11:00 AM
Upgrades For PagSeguro Digital Ltd (NYSE:PAGS), New Street Research upgraded the previous rating of Neutral to Buy. In…

ADPT

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $26

By Benzinga Newsdesk
November 10, 5:06 AM
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $30 to $26.

IONS

Read More
1 minute read
  • Earnings
  • News

Ionis Pharmaceuticals Q3 Sales $160.00M Beat $143.84M Estimate

By Benzinga Newsdesk
November 9, 8:05 AM
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly sales of $160.00 million which beat the analyst consensus estimate of $143.84 million by 11.23 percent. This is a 20.30 percent increase over sales of $133.00

IONS

Read More
1 minute read
  • FDA
  • News

Ionis Highlights Data From GSK’s Phase 2b Clinical Study Of Bepirovirsen

By Benzinga Newsdesk
November 8, 12:06 PM
onis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense

IONS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med

By Vandana Singh
September 23, 9:12 AM
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced topline data from the Phase 2b SOLANO study of ION449 (AZD8233) for hypercholesterolemia (high cholesterol levels).…

AZN

Read More
1 minute read
  • News

Ionis ION449 (AZD8233) Met Primary Endpoint in Phase 2b SOLANO Study for Patients with Hypercholesterolemia; Will Not Advance into Phase 3 Development Based on Pre-specified Criteria

By Charles Gross
September 23, 5:01 AM
Ionis Pharmaceuticals, Inc.

AZN

Read More
1 minute read
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Price Target
  • Trading Ideas
  • Upgrades

There’s ‘Outsized’ Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%

By Vandana Singh
September 9, 11:22 AM
Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with an Overweight (previously Underweight) rating and a price target of $57 from…

IONS

Posts navigation

1 2 … 10 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service